Biotech | August 12, 2021
Global cell expansion market poised for huge growth
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The company is eligible for 12 months exclusivity from launch
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
This work has been published in the journal ‘ACS applied materials and interface’
Subscribe To Our Newsletter & Stay Updated
